Demos Could Result From ‘Most Favored Nation’ Order

The Trump administration’s long-awaited executive order that seeks to tie U.S. drug prices to costs in other countries may represent more presidential campaign talking points than real policy that will take effect quickly. But analysts expect that the overarching issue of drug pricing will stick around, regardless of which candidate wins on Nov. 3.

For example, the executive order signals that the administration could pursue price caps for select Medicare Part B and D drugs in a possible second term. The order calls for demonstration projects to test “most favored nation” pricing in Parts B and D.

© 2022 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

workers-prepping-infusion-drug
May 12

Major PBMs Look Ahead to 2023 for Biosimilars Boom

READ MORE
wall-street-sign
May 12

Centene Plans to Sell Magellan Rx, PANTHERx Rare for $2.8 Billion

READ MORE
pills-and-dollars
May 12

Study: With High Prices, Rebate Revenue Is Growing for PBMs

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today